Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
XERS Xeris Pharmaceuticals, Inc. daily Stock Chart
XERS [NASD]
Xeris Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-4.54 Insider Own1.80% Shs Outstand26.94M Perf Week1.94%
Market Cap240.87M Forward P/E- EPS next Y-3.06 Insider Trans3.84% Shs Float26.46M Perf Month1.94%
Income-112.90M PEG- EPS next Q-1.07 Inst Own74.80% Short Float8.52% Perf Quarter-16.84%
Sales1.70M P/S141.69 EPS this Y-114.60% Inst Trans5.45% Short Ratio13.39 Perf Half Y11.75%
Book/sh1.62 P/B5.52 EPS next Y34.40% ROA-83.20% Target Price18.00 Perf Year-56.24%
Cash/sh3.80 P/C2.35 EPS next 5Y- ROE-150.10% 52W Range6.85 - 20.90 Perf YTD-47.41%
Dividend- P/FCF- EPS past 5Y- ROI-55.30% 52W High-57.46% Beta-
Dividend %- Quick Ratio6.00 Sales past 5Y- Gross Margin98.00% 52W Low29.78% ATR0.53
Employees134 Current Ratio6.00 Sales Q/Q-50.00% Oper. Margin- RSI (14)56.90 Volatility6.49% 6.46%
OptionableYes Debt/Eq0.00 EPS Q/Q-71.30% Profit Margin- Rel Volume0.41 Prev Close8.94
ShortableYes LT Debt/Eq1.33 EarningsNov 06 Payout- Avg Volume168.34K Price8.89
Recom- SMA206.56% SMA505.31% SMA200-12.50% Volume50,358 Change-0.56%
Jul-16-18Initiated RBC Capital Mkts Outperform $24
Jul-16-18Initiated Leerink Partners Outperform $24
Jul-16-18Initiated Jefferies Buy $23
Dec-02-19 06:37AM  Trade Alert: The President Of Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), Paul Edick, Has Just Spent US$153k Buying Shares Simply Wall St.
Nov-29-19 01:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-21-19 06:00AM  Xeris Pharmaceuticals Provides a Business Update During Recent Investor Conference GlobeNewswire
Nov-07-19 03:09PM  Is Xeris Pharmaceuticals, Inc. (XERS) A Good Stock To Buy? Insider Monkey -7.74%
11:45AM  Xeris Pharmaceuticals, Inc. (XERS) Reports Q3 Loss, Tops Revenue Estimates Zacks
08:00AM  Xeris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights GlobeNewswire
Nov-01-19 04:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +6.60%
Oct-30-19 10:33AM  Earnings Preview: Xeris Pharmaceuticals, Inc. (XERS) Q3 Earnings Expected to Decline Zacks
Oct-25-19 02:22PM  Does Xeris Pharmaceuticals (NASDAQ:XERS) Have A Healthy Balance Sheet? Simply Wall St.
Oct-01-19 08:00AM  Xeris Pharmaceuticals Appoints Mark Thierer to Board of Directors GlobeNewswire -5.29%
Sep-27-19 04:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Sep-19-19 08:00AM  Xeris Pharmaceuticals Begins Dosing Patients in a Phase 2 Clinical Trial Evaluating Its Novel Fixed-Ratio Co-Formulation of Pramlintide-Insulin for Diabetes Business Wire
Sep-10-19 11:58AM  UPDATE 2-Xeris Pharma's low blood sugar treatment wins FDA approval Reuters -10.97%
11:43AM  Xeris Pharma's low blood sugar treatment wins FDA approval Reuters
11:31AM  Xeris Pharmaceuticals Announces Expanded $85 Million Debt Facility With Oxford Finance and Silicon Valley Bank Business Wire
11:30AM  Xeris Pharmaceuticals Receives U.S. FDA Approval for GVOKE (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia Business Wire
07:36AM  The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris Benzinga
Sep-04-19 11:34AM  Have Insiders Been Buying Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Shares? Simply Wall St. -5.85%
Aug-30-19 04:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) GlobeNewswire
Aug-29-19 05:00PM  Xeris Pharmaceuticals to Present at Two September Healthcare Conferences GlobeNewswire
Aug-06-19 07:45PM  Xeris Pharmaceuticals, Inc. (XERS) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM  Xeris Pharmaceuticals Announces Second Quarter 2019 Financial Results and Highlights GlobeNewswire
Aug-05-19 10:31AM  Xeris Pharmaceuticals, Inc. (XERS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks -5.58%
Aug-02-19 04:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire -6.20%
Jul-18-19 01:09PM  Did Changing Sentiment Drive Xeris Pharmaceuticals's (NASDAQ:XERS) Share Price Down By 38%? Simply Wall St.
Jun-28-19 04:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +6.42%
Jun-27-19 08:00AM  Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Developmental Ready-to-use Glucagon in Patients at Risk From Hypoglycemia Following Bariatric Surgery Business Wire
Jun-17-19 08:00AM  Xeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon Business Wire +8.43%
May-25-19 09:03AM  Can We See Significant Institutional Ownership On The Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Share Register? Simply Wall St.
May-09-19 04:05PM  Xeris Pharmaceuticals Announces First Quarter 2019 Financial Results and Highlights Its Pipeline GlobeNewswire +5.35%
May-01-19 08:00AM  Xeris Pharmaceuticals Announces Results From a Phase 1 Study of Its Novel Formulation of Diazepam GlobeNewswire
Apr-26-19 04:01PM  Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-29-19 04:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire
Mar-25-19 08:45AM  Xeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use Glucagon Business Wire
Mar-14-19 04:15PM  Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia Business Wire
Mar-12-19 03:36PM  How Many Insiders Bought Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Shares? Simply Wall St.
Mar-06-19 04:10PM  Xeris Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline Progress GlobeNewswire
Mar-01-19 04:15PM  Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Feb-20-19 07:30AM  Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-13-19 07:26PM  Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock GlobeNewswire -8.67%
Feb-12-19 04:33PM  Why Molson Coors Brewing, Xeris Pharmaceuticals, and Varonis Systems Slumped Today Motley Fool -21.50%
08:04AM  The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares Benzinga
Feb-11-19 04:05PM  Xeris Pharmaceuticals Announces Proposed Public Offering of Shares of Common Stock GlobeNewswire
Dec-20-18 08:30AM  European Medicines Agency Grants Orphan Drug Designation for Xeris Investigational Ready-to-Use Glucagon for the Treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS) Business Wire -11.96%
Nov-07-18 08:00AM  Xeris Pharmaceuticals Announces Third Quarter 2018 Financial Results and Highlights Pipeline Progress GlobeNewswire
Oct-23-18 08:30AM  Xeris Pharmaceuticals Announces FDA Acceptance for Review of NDA for Its Ready-to-Use Glucagon Rescue Pen Business Wire
Aug-17-18 08:30AM  Xeris Pharmaceuticals and OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris Novel Ready-to-Use Liquid Glucagon Business Wire
Aug-13-18 08:00AM  Xeris Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Highlights GlobeNewswire
Jul-31-18 07:00AM  Xeris Pharmaceuticals to Present at Two Upcoming Investor Conferences GlobeNewswire
Jul-30-18 07:00AM  Xeris Pharmaceuticals Announces New Board Members and New Executive to Management Team GlobeNewswire
Jun-26-18 04:15PM  Xeris Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jun-25-18 04:15PM  Xeris Pharmaceuticals Announces Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen Business Wire
Jun-21-18 11:41AM  [$$] Banner Day for Biotech as Five Drug Developers Go Public The Wall Street Journal
Jun-20-18 06:31PM  Xeris Pharmaceuticals Announces Pricing of Initial Public Offering of Common Stock GlobeNewswire
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that is in Phase II clinical trials for the treatment of congenital hyperinsulinism, post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, and hypoglycemia-associated autonomic failure, as well as for treating hypoglycemia associated with intermittent and chronic conditions, and bi-hormonal artificial pancreas closed-loop systems. In addition, it develops continuous subcutaneous glucagon infusion system of ready-to-use glucagon; ready-to-use diazepam formulation, which is in Phase I clinical trial for the treatment of acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is in pre-clinical stage for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Edick Paul RSee RemarksNov 25Buy8.5517,935153,283172,935Nov 27 04:43 PM
open in yahoo | open in reuters | open in google